These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 18221974)

  • 1. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands.
    Löwenberg M; Stahn C; Hommes DW; Buttgereit F
    Steroids; 2008 Oct; 73(9-10):1025-9. PubMed ID: 18221974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.
    Stahn C; Löwenberg M; Hommes DW; Buttgereit F
    Mol Cell Endocrinol; 2007 Sep; 275(1-2):71-8. PubMed ID: 17630118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and nongenomic effects of glucocorticoids.
    Stahn C; Buttgereit F
    Nat Clin Pract Rheumatol; 2008 Oct; 4(10):525-33. PubMed ID: 18762788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression.
    Löwenberg M; Verhaar AP; van den Brink GR; Hommes DW
    Trends Mol Med; 2007 Apr; 13(4):158-63. PubMed ID: 17293163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.
    Schäcke H; Rehwinkel H; Asadullah K; Cato AC
    Exp Dermatol; 2006 Aug; 15(8):565-73. PubMed ID: 16842594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
    Huisman AM; Jacobs JW; Buttgereit F; Bijlsma JW
    Ned Tijdschr Geneeskd; 2006 Mar; 150(9):476-80. PubMed ID: 16553045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
    Schäcke H; Berger M; Rehwinkel H; Asadullah K
    Mol Cell Endocrinol; 2007 Sep; 275(1-2):109-17. PubMed ID: 17630119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?
    Newton R; Holden NS
    Mol Pharmacol; 2007 Oct; 72(4):799-809. PubMed ID: 17622575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
    Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-genomic glucocorticoid effects to provide the basis for new drug developments.
    Song IH; Buttgereit F
    Mol Cell Endocrinol; 2006 Feb; 246(1-2):142-6. PubMed ID: 16388891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized glucocorticoid therapy: teaching old drugs new tricks.
    Strehl C; Buttgereit F
    Mol Cell Endocrinol; 2013 Nov; 380(1-2):32-40. PubMed ID: 23403055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociated glucocorticoid receptor ligands.
    Schäcke H; Rehwinkel H
    Curr Opin Investig Drugs; 2004 May; 5(5):524-8. PubMed ID: 15202726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index.
    Schäcke H; Rehwinkel H; Asadullah K
    Curr Opin Investig Drugs; 2005 May; 6(5):503-7. PubMed ID: 15912964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects.
    McMaster A; Ray DW
    Exp Physiol; 2007 Mar; 92(2):299-309. PubMed ID: 17138619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nongenomic effects of glucocorticoids].
    Grzanka A; Jarzab J
    Pneumonol Alergol Pol; 2009; 77(4):387-93. PubMed ID: 19722144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of novel glucocorticoid receptor modulators.
    Berlin M
    Expert Opin Ther Pat; 2010 Jul; 20(7):855-73. PubMed ID: 20553093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation.
    Brewer JA; Khor B; Vogt SK; Muglia LM; Fujiwara H; Haegele KE; Sleckman BP; Muglia LJ
    Nat Med; 2003 Oct; 9(10):1318-22. PubMed ID: 12949501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells.
    Boldizsar F; Talaber G; Szabo M; Bartis D; Palinkas L; Nemeth P; Berki T
    Immunobiology; 2010 Jul; 215(7):521-6. PubMed ID: 19906460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin B6 modulates glucocorticoid-dependent gene transcription in a promoter- and cell type-specific manner.
    Bamberger CM; Else T; Ellebrecht I; Milde-Langosch K; Pankoke D; Beil FU; Bamberger AM
    Exp Clin Endocrinol Diabetes; 2004 Nov; 112(10):595-600. PubMed ID: 15578335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic signaling pathways in rapid, nongenomic action of glucocorticoid.
    Chen YZ; Qiu J
    Mol Cell Biol Res Commun; 1999; 2(3):145-9. PubMed ID: 10662589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.